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Static mechanical allodynia (SMA) is a paradoxical painful
hypo-aesthesia: Observations derived from neuropathic pain
patients treated with somatosensory rehabilitation
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Abstract
The present study aimed at investigating the time span it takes to remove a static mechanical allodynia (SMA) in humans
suffering from chronic peripheral neuropathic pain. Forty-three subjects were included in the study and, during
somatosensory rehabilitation, their SMA territory was precisely mapped. They then underwent distant vibrotactile counter
stimulation (DVCS) treatment. It was observed that, with DVCS, SMA disappeared in all cases, and was transformed into
an underlying hypoaesthesia. It was found that the ‘‘tenderness to touch’’ symptom (which is SMA) was located in the same
territory as the underlying hypoaesthesia, which was located on a part of the cutaneous territory of a partially damaged nerve.
These results demonstrate that treating patients suffering from neuropathic pain with DVCS revealed a skin territory of
denervation that was previously masked by SMA. Thus, SMA can be considered as a paradoxical painful hypoaesthesia.
Furthermore, mapping SMA is a valuable source of information for our understanding of abnormal sensory processing in
neuropathic pain patients. We conclude that the mapping of the zone of hypersensitivity on the skin in humans suffering from
chronic peripheral neuropathic pain improves diagnosis. The mapping of the zone of hypersensitivity is a tool to presume
which branch of the peripheral nerve is damaged. The location of the axonal lesions is at the periphery, while the mechanism
of pain sensitization is probably central and referred peripherally to the skin by a painful hypoaesthesia.
Keywords: Hypersensitivity, burning sensation, extraterritorial neuropathic pain, axotomy, peripheral neuropathic pain,
hypoaesthesia
Introduction
Mechanical allodynia (MA) was first defined in
humans by Merskey (1979) and revised a few years
later: MA is a ‘‘Pain due to a stimulus which does not
normally provoke pain’’ (Merskey and Bogduk
1994). More specifically, MA is a neuropathic pain
provoked by application of a tactile stimulus which
normally does not elicit pain on the skin. Based on
the recommendations of the IASP (International
Association for the Study of Pain), MA is distinct
from hyperalgesia, a term reserved for an increase of
pain sensitivity to a noxious stimulus. There has been
much debate on the topic of peripheral neuropathic
pain, in particular on the issue of whether MA is
caused by damaged A fibres. A possible reason for
the controversies about the mechanisms underlying
MA is that MA is fundamentally paradoxical. Partial
denervation of the skin is expected to blunt sensa-
tion, not to amplify it in a noxious way (Sukhotinsky
et al. 2004; Devor 2006). The term ‘‘burning
numbness’’ has been used to describe this paradox
(Campa and Payne 1993). A second reason for a
debate on MA, namely, considering MA as an
expression of A fibre lesions, is that the location
of the axonal lesions at the periphery is distinct from
the site of pain sensitization.
MA is believed to be initiated by a massive,
spontaneous ectopic firing originating from the
neuroma as well as in axotomized sensory neurons
in dorsal root ganglia, occurring a few hours after a
lesion of a peripheral nerve (e.g., Sukhotinsky et al.
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2004). The ectopic firing then leads to initiation and
maintenance of central sensitization (Sukhotinsky
et al. 2004; Devor 2006), most likely due to
neurochemical changes taking place in the spinal
cord (e.g., Ji and Woolf 2001). In line with this
interpretation, when the ectopic peripheral input was
suppressed, central sensitization decreased and MA
was eliminated (Devor 2006). The mechanism of
central sensitization, leading to a decrease of pain
threshold in the spinal cord, was referred to an
increased synaptic efficacy, reminiscent to some
extent of the synaptic plasticity underlying long-
term potentiation (LTP) in the hippocampus or
cerebral cortex (Ji et al. 2003). It is believed that in
the presence of central sensitization, inputs along
intact low-threshold cutaneous afferents in the
territories of neighbouring not-injured nerves pro-
voke pain in response to light tactile stimulation (e.g.,
Cervero and Laird 1996; Campbell and Meyer 2006)
[overlapping pain (Rowbotham and Fields 1989;
Rowbotham et al. 1996b; Fields et al. 1998) or
extraterritorial pain (Decosterd and Woolf 2000;
Malan et al. 2000)]. More specifically, synaptic
efficacy is considered to be initially increased in the
nociceptors (homotypic potentiation) leading in a
second step, to increase of efficacy in synapses
formed by low-threshold mechano-sensitive A
fibres (Ji et al. 2003). Whereas pain caused by light
touch (allodynia) is related to signals transferred by
A fibres, secondary hyperalgesia in adjacent terri-
tories is mediated by - or C-nociceptors (e.g.,
Ziegler et al. 1999). This stage of allodynia-like signs
in not-injured nerve territories probably reflects the
increase of sensitivity in the primary sensory neurons
due to an abnormal excitable peripheral state as well
as the increase in excitability and extension of
receptive fields of dorsal horn neurons related to
central sensitization (Decosterd 2006). The phenom-
enon of central sensitization extended to A fibres
leads to a misunderstanding of the symptom being
detected peripherally by stimulating the skin.
Another potential generator of neuropathic pain is a
possible contribution of the intact nociceptors. Their
firing pattern is modified as a result of local exposure
at the periphery to damaged fibres subjected to a
process of Wallerian degeneration. This second
mechanism would thus correspond to a kind of
peripheral sensitization (e.g., Campbell 2001; Wu
et al. 2001; Campbell and Meyer 2006). Along this
line, a recent study reported a long-term change of
sympathetic and sensory innervations of the skin after
peripheral nerve injury, which may be involved in the
development and maintenance of neuropathic pain
(Yen et al. 2006). In animal models of neuropathic
pain, MA is observed in specific territories that are
related to the type of injury, for instance, traumatic,
compressive, infectious, systemic, etc. (Bennett and
Xie 1990; Kim and Chung 1992; Decosterd and
Woolf 2000; Ossipov et al. 2000; Campbell and
Meyer 2006).
The definition of MA includes the amplitude of
the stimulus and the intensity of the perceived pain.
A third parameter that is also involved in the
definition of MA is the territory to which the stimulus
is applied and how the stimulus is applied. MA is
usually tested by applying a brush stroke on the skin.
As the stimulus is moved on the skin surface, this
brush-evoked allodynia is in fact a dynamic MA, for
which a standardized test is difficult to define (no
precise control of the site of application and of the
amplitude of tactile stimulation), thus raising ques-
tions about its reliability. In the present study, the
stimulus used to delineate a territory of MA is a static
force of 15 g applied perpendicularly with an
aesthesiometer at a punctuate site on the skin
(Spicher 2006). As the stimulus is not displaced in
parallel to the skin surface, we introduce here the
term of static mechanical allodynia (SMA), reflecting
the static stimulus application mode. The application
of the same stimulus is then repeated at different
punctuate sites on the skin, to precisely delineate the
SMA territory, a procedure referred to as ‘‘allodyno-
graphy’’ (as shown in Figure 1).
In humans, the territory on the skin eliciting this
pain symptom of burning sensation (or SMA) can be
precisely mapped by establishing its ‘‘allodyno-
graphy’’, as shown in Figure 1A for a patient
exhibiting a well-defined SMA territory on the lateral
side of the right foot (violet area). We report here
data derived from 43 patients suffering from nerve-
injury-induced SMA, altogether exhibiting 63 SMA
territories determined by allodynography. During
several weeks, the patients were then subjected to
somatosensory rehabilitation, consisting of gentle,
distant vibrotactile counter stimulation (DVCS)
treatment. The vibratory tactile stimulus (100Hz)
is applied first at some distance from the SMA
territory but, session after session, it progressively
and slowly invades the SMA territory forming new
zones where the stimulus is not perceived as painful
anymore but comfortable. Using this approach, the
aim of the present paper is to test the hypothesis that
the initial SMA territory is transformed into a
hypoaesthetic territory as a result of DVCS treat-
ment. In other words, the effect of the DVCS therapy
is to provoke a progressive shrinkage of the SMA
territory, revealing the presence of an underlying
mechanical hypoaesthesia.
Materials and methods
Forty-three patients were included in the study,
based on the following inclusion criteria
(Table I): first, presence of neuropathic pain and
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SMA on the day of initial testing; second, as a result
of the somatosensory rehabilitation, the SMA terri-
tory disappeared at the time of analysis. Overall,
amongst the 241 neuropathic pain patients treated in
the Somatosensory Rehabilitation Centre (Fribourg,
Switzerland), from July 2004 until November 2005,
159 patients presented a hypoaesthesia and 82
presented a SMA. Patients with persisting SMA in
Figure 1. (A) Example of allodynography in a typical patient, delineating the violet territory on the foot (lateral calcaneal
nerve) where the application of a force of 15 g provoked a touch-evoked pain (SMA) of 3/10 cm on the visual analogue scale
(VAS) of pain (see Appendix A). (B) Time course of the progressive shrinkage of the SMA territory, as a result of treatment
from 4 March (t0) until 14 July 2005 (t6); t1 is the time interval in days separating the day of testing from t0 etc. The date at
which a complete disappearance of the SMA territory was observed is 14 July 2005, replaced by the underlying hypoaesthesia
of the lateral calcaneal nerve. (C) Time course of the progressive shrinkage of the SMA territory for the anterior branch of
medial cutaneous nerve of the forearm. Same conventions as in B. (d) The time course of the progressive shrinkage of the
SMA territory for the lateral cutaneous branch of the 6th intercostal nerve. Same conventions as in B.
Table I. Origin of the 43 patients with peripheral neuropathic pain syndromes and their 63 static mechanical allodynia (SMA) territories
included in the study out of a larger population of 241 neuropathic pain patients under somatosensory rehabilitation.
159 patients with initial hypoaesthesia
22 patients interrupted their DVCS treatment
17 patients still under treatment at onset of the analysis
241 neuropathic
pain patients
82 patients
with SMA
60 patients
treated with DVCS
43 patients for whom the 63 SMA
territories have already disappeared
at onset of the analysis
The 241 neuropathic pain patients were treated in the Somatosensory Rehabilitation Centre (Fribourg), from 1 July 2004 until
23 November 2005. One hundred and fifty-nine neuropathic pain patients presented a hypoaesthesia. Eighty-two neuropathic pain patients
presented a SMA. Twenty-two patients interrupted their distant vibrotactile counter stimulation (DVCS) treatment. By 23 November 2005,
17 patients still remained with an incomplete disappearance of SMA (treatment ongoing).
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November 2005 (n¼ 17) or who interrupted their
somatosensory rehabilitation before its disappear-
ance (n¼ 22) were discarded as they did not fulfil the
inclusion criteria. These interruptions of treatment
were due either to the incidence of another medical
disorder (e.g., stroke) or the free choice by the
patient to follow another treatment (e.g., acupunc-
ture). Finally, 43 patients were included in the study
(Table I). No patient presenting neuropathic pain
and SMA at the beginning of the somatosensory
rehabilitation followed by disappearance of SMA
after treatment (inclusion criteria) was excluded.
From the day of the initial testing, the mean
duration of the neuropathic chronic pain (defined
as a pain lasting 6 months or more) presented
by the 43 patients suffering from SMA was 35
monthsSD¼ 21 months (range: 7–523 months).
Patients were usually sent to the Somatosensory
Rehabilitation Centre by a prescribing medical
doctor in order to be tested and rehabilitated
according to the somatosensory rehabilitation
method described below (see also Dellon 2000;
Spicher 2006).
Procedure
Three therapists treated the 43 patients for their
SMA and performed the tests described below. Each
patient was individually assessed by at least two of the
three therapists. The somatosensory rehabilitation
was organized on the basis of one weekly session,
with another therapist every other week (two
therapists in total, but not three). The tests were
performed during the treatment sessions in the same
room in which the temperature was maintained at
20 1C. As a result of the therapy, the SMA
territory progressively shrank, and along the con-
secutive sessions, the time course of progressive
SMA territory shrinkage until disappearance was
assessed using either allodynography or the rainbow
pain scale procedure (see below), but never using
both simultaneously (see Discussion).
Somatosensory testing
Two tests were used to quantify the progressive
impact of SMA treatment, as previously reported
(Spicher 2006):
. The allodynography, quantifying the location
and extent of the SMA territory (Appendix A
and Figure 1A).
. The rainbow pain scale, quantifying the severity
of the SMA (Appendix B and Figure 2).
Allodynography (see Appendix A for a detailed descrip-
tion of the procedure). The allodynography (Spicher
2006) is a technique to quantify and map a SMA
territory on the skin, a test inspired by a definition of
allodynia: ‘‘Gentle mechanical stimuli (e.g. bending
of hairs) may evoke severe pain’’ (Fields 1994).
The test is conducted by varying the application site
of the stimulus in order to delineate the borders of
the SMA territory. This test allows visual inspection
Figure 2. A territory corresponding to the blue colour on the rainbow pain scale (panel A; see Appendix B) is smaller at the
same date than its allodynography (panel B). The touch-evoked pain (SMA) is the same (VAS¼ 3/10 cm), but the
application force was different: panel A, 3.6 g; panel B, 15 g. The skin territory corresponds a posteriori to the innervation
zone of an anterior branch of the medial cutaneous nerve of forearm.
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(both by the therapist and the patient) of the
progressive SMA territory shrinkage during treat-
ment. Figures 1B–D show how allodynography—
when conducted at time intervals of usually 2–4
weeks—monitors the progressive shrinkage of the
SMA territory.
Rainbow pain scale (Appendix B). The rainbow pain
scale (Spicher 2006) is a procedure aimed at
establishing the severity of the SMA. Symbolically,
this test passes through the seven colours of the
rainbow (Figure 2), going from red to violet, each
colour corresponding to increasing force levels
(0.03–15 g), applied using aesthesiometers
(Figure 3A). In order to map the SMA territory,
the contour of the painful skin territory is determined
using a 15 g aesthesiometer (corresponding to violet
in the rainbow pain scale). As the pain tolerance
threshold of the patient was strictly respected during
this procedure, the SMA territory itself was not
touched with the 15 g aesthesiometer. Nevertheless,
it was possible to investigate the severity of the SMA
by testing the painful territory with lighter pressure
forces tolerated by the patient. The rainbow pain
scale is then an estimate of the pain intensity within
the SMA territory, obtained by application of the
slightest aesthesiometer (going from red to violet)
provoking pain. The pain invariant is defined as 3 cm
from the left on a visual analogue scale (VAS) of a
total length of 10 cm, in the absence of spontaneous
neuropathic pain at rest (red line in Figure 3B, top).
In contrast, if the patient has spontaneous neuro-
pathic pain at rest, the pain invariant is defined as the
pain at rest þ 1 cm. For instance, if the pain at rest
assessed by the patient the day of testing is 4, then the
pain invariant is 5 (Figure 3B, bottom). Figure 2
illustrates that, as expected, the blue rainbow pain
scale (3.6 g) is smaller than the SMA territory
derived from allodynography (15 g).
Once the SMA progressively disappeared as a
result of the DVCS treatment, two tests were used to
demonstrate the presence of an underlying
hypoaesthesia:
. The secondary aesthesiography, providing an
estimate of the location and extent of the
underlying hypoaesthesia (Appendix C and
Figure 4B).
. The pressure perception threshold (PPT),
quantifying the amplitude of the underlying
hypoaesthesia.
Secondary aesthesiography (Appendix C). The sec-
ondary aesthesiography is conducted after complete
shrinkage of the SMA territory, with the aim to
quantify the underlying hypoaesthesia. The term
‘‘aesthesiography’’ is used because it refers to a
mapping of the hypoaesthesia, while ‘‘secondary’’ is
used to avoid any misunderstanding with proper
aesthesiography (Le´tie´vant 1876; Trotter and Davies
1907; Tinel 1917; Inbal et al. 1987; Spicher and
Kohut 2001). Aesthesiography is a very sensitive test,
which is part of the diagnosis of axonal lesions
(Spicher et al. 2005; Spicher 2006). By definition,
the SMA is considered as ‘‘disappeared’’ when the
application of an aesthesiometer of 15 g does no
longer elicit pain, representing the onset of secondary
aesthesiography. Figure 4 illustrates the transition
from SMA to underlying hypoaesthesia.
Short-form pressure perception threshold. The PPT,
introduced by von Frey (1896), is a test used to
determine the patient’s ability to perceive the
application of a force on the skin. It is conducted
Figure 3. (A) Aesthesiometer kit used to conduct the rainbow pain scale test (see Appendix B). (B) The pain invariant is
defined by the therapist with a red line at 3 cm from the left (top) on a visual analogue scale (VAS) of a total length of 10 cm,
in the absence of spontaneous neuropathic pain at rest (green line). In contrast, if the patient has spontaneous neuropathic
pain at rest defined by himself with a green line (bottom), the pain invariant is defined as the pain at rest þ1 cm (red line
drawn by the therapist). If the pain at rest assessed by the patient the day of testing is 4, then the pain invariant is 5.
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during the session following the disappearance of the
SMA. If applied earlier, when the SMA is still
present, the application of the stimulus may trigger a
reappearance of the SMA. We have chosen the test
application proposed by Semmes et al. (1960) and
modified later by Malenfant et al. (1998), to reduce
the duration of the test and also to diminish the risk
of SMA reappearance. The PPT is based on the
application of seven aesthesiometers (from the kit of
20) (for more details, see Spicher 2006). The short-
form PPT score is given by the mean value of
the force application of the three aesthesiometers
detected in an ascending, descending, and ascending
series (ADA) (Spicher et al. 2006).1 In the ascending
series (from the thinnest to the thickest of the seven
aesthesiometers), it is the first one detected by the
patient. In the descending series (from the thickest to
the thinnest), it is the last one detected.
Somatosensory rehabilitation
The somatosensory rehabilitation offered to the 43
patients was based on a method developed in the
Somatosensory Rehabilitation Centre and described
earlier in detail (Spicher 2006). This method can be
taught to a therapist in 35 h. Briefly, the duration of
each weekly session of somatosensory rehabilitation
ranges between 30 and 75min (average time:
45min). The somatosensory rehabilitation comprises
three treatment phases: (1) Distant vibrotactile
counter stimulation (DVCS), in the presence of a
possible allodynic territory (which was the case
initially for the 43 patients in the present study).
(2) Rehabilitation of hyposensitivity. (3)
Desensitization by mechanical vibrations at the site
of axonal lesions. The DVCS treatment begins in the
presence of a SMA territory (Table II) and is
pursued until its complete disappearance, at which
time the rehabilitation of hyposensitivity on the
hypoaesthetic territory can be initiated. The aims of
the rehabilitation of hyposensitivity are to diminish
the hypoaesthesia and to attenuate simultaneously
the spontaneous neuropathic pain. In the present
study, the somatosensory rehabilitation is described
only for its first phase, the DVCS treatment, aimed at
eliminating the SMA territory.
Distant vibrotactile counter stimulation
(DVCS). Distant vibrotactile counter stimulation
(Spicher 2006) is a neologism. This new technique
uses a tactile and vibratory device, allowing the
patient to perceive a non-nociceptive stimulus in a
non-nociceptive manner on a cutaneous territory
that is initially allodynic. The variable parameter of
the DVCS is the localization of the stimulus
application, but not its amplitude. At this point, the
task of the somatosensory therapist is:
(i) First, to presume which branch of the cuta-
neous nerve affected is damaged. It is not
possible to determine it at this stage, as the
extraterritorial pain is overlapping the cuta-
neous distribution of the damaged nerve.
(ii) To define a limited zone of the skin where
DVCS should be applied once a week in the
presence of the therapist at the rehabilitation
centre and to train the patient to perform his
own therapy by application of tactile stimuli, 6
times a day for 1min at home.
(iii) To delineate a limited zone of the skin to be
avoided as much as possible.
Figure 4. When the SMA territory determined by allodynography disappeared (panel A), the presence of an underlying
hypoaesthetic territory was found, based on a secondary aesthesiography procedure (panel B; see Appendix C). (A)
Allodynography (31 August 2005, the application of a force of 15 g provoked a touch-evoked pain (SMA) of 3/10 cm on the
VAS). (B) Secondary aesthesiography (19 October 2005, the application of a force of 0.2 g was not detected).
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The cutaneous zone to counter stimulate, per-
ceived as comfortable, and the zone to avoid,
perceived as less comfortable, are tested and defined
at each session. The results are presented to the
patient on a map. During the course of treatment, it
will become possible for the patient to progressively
invade the ‘‘old’’ allodynic territory with the same
comfortable stimulus. Figure 5 illustrates how the
zones of application of DVCS invade the SMA
territory, which progressively disappears. The SMA
is treated by distant tactile counter stimulation (i.e.,
rabbit skin) at home and by DVCS during the weekly
therapeutic session at the rehabilitation centre (para-
meters of stimulation: frequency 100Hz; amplitude
0.06mm) (Spicher et al. 2005). In sharp contrast to
previous reports (Rowbotham et al. 1996a; Galer
et al. 1999), the counter stimulus is not applied on
the painful skin.
Figure 5. Schematic diagram showing the progressive change of the skin zone on the forearm (in green) where to apply the
‘‘distant vibrotactile counter stimulation (DVCS)’’, together with the skin area to avoid (in red). (A–C) The counter
stimulated zone progressively invaded the zone that was to be avoided (i.e., the presumed anterior branch of medial cutaneous
nerve of the forearm damaged). The time intervals between the sessions in panels A, B, and C is given in days. (d) During the
same period, the SMA territory progressively disappeared (for more details see also the legend of Figure 1C). The day when
the SMA disappeared (t3¼ 50 days after onset of DVCS treatment), the underlying hypoaesthesia appeared and the DVCS
treatment was interrupted. A posteriori, as the skin territory of the underlying hypoaesthetic territory corresponds to the
innervation of an anterior branch of medial cutaneous nerve of forearm, we concluded that the aetiology of the SMA was a
lesion of the anterior branch of medial cutaneous nerve of the forearm.
Table II. In presence of SMA, the rehabilitation of the hyposensibility is preceded by the DVCS
to treat the touch-evoked pain.
Touch-evoked pain Spontaneous pain
Static mechanical
allodynia (SMA)
Yes Rehabilitation of the
underlying hyposensibility
#
DVCS
Hypoaesthesia
(not included in this study)
No Rehabilitation of the
hyposensibility
!
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Results
Subjects: Neuropathic pain syndromes
Table III shows the neuropathic pain syndromes
presented by the 43 patients on the day of initial
testing. Table IV shows the severity of peripheral
chronic neuropathic pain symptoms, as established
for the 43 patients at initial testing. The less severe
mechanical allodynia was found in patients exhibit-
ing a SMA characterized by an absence of pain at rest
(Stage II). The neuralgic prodrome (Stage III) is
distinguished from the neuralgic syndrome (Stage
IV): the former has intermittent pain whereas the
latter has persistent pain (Spicher 2006). Finally,
Complex Regional Pain Syndrome of type II (Bruehl
et al. 1999) corresponds to a peripheral neuropathic
pain syndrome (Stage V) (Mackinnon 1988; Gracely
et al. 1992; Albrecht et al. 2006; Oaklander et al.
2006), characterized by the boiling sensation (‘‘as if
eggs were being boiled in the limb’’; Mitchell 1872).
In the present study, each patient presented a SMA,
but neuropathic syndromes may, of course, also
occur with an initial hypoaesthesia.
Branch of cutaneous nerve damaged
Forty-three patients were included in the study. As
we hypothesize that the initial SMA territory is
transformed into a hypoaesthetic territory, the
somatosensory therapist must presume the branch
of the nerve damaged in order to define the DVCS
treatment guidelines. Due to the phenomenon of
extraterritorial pain, at that step, the somatosensory
therapist can thus only presume the branch of the
nerve affected by the lesion. Thus the identification
of the branch of the nerve damaged can be done only
a posteriori, when the underlying hypoaesthesia
appears. Table V lists the cutaneous nerves that
were damaged in the group of the 43 patients
presenting overall 63 SMA territories. Some of the
patients had more than one (two or three) SMA
territory, such as a brachial neuralgia and an
intercostal neuralgia.
Painful hypoaesthesia disappearance
After DVCS treatment, the 63 SMA territories
disappeared (inclusion criterion). We observed that
100% of them switched into a hypoaesthetic terri-
tory, referred to as underlying hypoaesthesia. None
of the SMA territory became immediately normo-
sensitive at the end of the DVCS treatment
(Table VI).
Time course of SMA disappearance as a result of
DVCS treatment
On average, a period of 70 days, thus 10 sessions,
SD¼ 66 days (range: 8–206 days) of treatment
(DVCS) was necessary to eliminate the SMA. To
address the issue of whether the duration of DVCS
treatment is related to the severity of the SMA, the
progressive disappearance of each colour in the
rainbow pain scale into the next colour was investi-
gated. For example, in the case of SMA territory 47,
the green aesthesiometer (1.5 g) did not evoke pain,
but the next aesthesiometer did (the ‘‘blue’’ aesthe-
siomether—3.6 g), on the date of the initial somato-
sensory testing.When the blue aesthesiometer did not
provoke pain anymore, the rainbow pain scale
switched into indigo (8.7 g), eliciting the invariant
pain (i.e., 3 cm/10 cm on the VAS).
Table IV. Severity of peripheral neuropathic pain symptoms (n¼ 43 patients).
Stage Diagnosis Neuropathic pain System Number
Stage II Simple mechanical allodynia Pressure-evoked pain without spontaneous pain Somatosensory 5
Stage III Neuralgic prodromea Pressure-evoked pain and intermittent pain Somatosensory 15
Stage IV Neuralgic syndromea Pressure-evoked pain and persistent pain Somatosensory 16
Stage V CRPS IIa Pressure-evoked pain and sensation of boiling Sympathetic 7
Somatomotor
Somatosensory
a With initial SMA in this study, but these syndromes may also present a hypoaesthesia (see Table I: 159 patients with initial
hypoaesthesia).
Note: Patients with basic cutaneous disorders and no neuropathic pain (Stage I) were not included.
Table III. Summary of peripheral neuropathic pain
syndromes observed on initial examination of the
patients (n ¼ 43).
Diagnosis
Number
of patients
Trigeminal neuralgia 2
Occipital neuralgia 1
Cervical neuralgia 2
Brachial neuralgia 8
Intercostal neuralgia 8
Lumbo-abdominal neuralgia 2
Femoral neuralgia 8
Meralgia paraesthetica 1
Sciatic neuralgia 11
Total 43
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Figure 6 illustrates the distribution of the colour
transitions in the rainbow pain scale and their stages
of disappearance colour by colour for the 63 SMA
territories analysed in the present study. Moreover,
Figure 6 shows the distribution of the initial touch-
evoked pain severity for all SMA territories included
in the study. On average, 24 days of treatment were
necessary to transform step by step the 158 rainbow
pain scale colours into the next colour. The time
course of disappearance from one rainbow pain scale
value into the next one is not linear (Figure 7).
It takes longer to overcome a green rainbow
pain scale (1.5 g provoking pain) than to overcome
a blue rainbow pain scale (3.6 g). It takes 49.9
daysSD¼ 32.9 days to overcome a green rainbow
pain scale whereas it takes 33.7 daysSD¼ 20.8
days to overcome a blue rainbow pain scale.
Quality of the underlying hypoaesthesia
In the session following the disappearance of SMA,
the quality of the underlying hypoaesthesia was
measured by the short-form PPT. The average
PPT was 7.8 gSD¼ 14.9 g (range: 0.3–75 g),
independently of the cutaneous distribution of the
corresponding nerve damage. This result shows the
presence of a clear hypoaesthesia, as normal values
for PPT are below 1 g, irrespective of the body
location.
Discussion
In the present study, 100% of the SMA territories
(n¼ 63) investigated and treated on the skin of 43
patients completely disappeared, replaced by an
underlying hypoaesthetic territory, which was then
treated at a later stage. This clinically highly
significant result was obtained using the DVCS
treatment: weekly in therapy and daily at home by
application of tactile stimuli 6 times a day for 1min.
To our knowledge, this is the first report on such a
phenomenon in the field of chronic neuropathic pain
syndromes in humans. Although the present treat-
ment has been introduced first to handle neuropathic
pain at the level of the forearm, more specifically the
hand, our data demonstrate that this therapeutic
Table V. Distribution of axonal lesions by the cutaneous department (Valleix’s Neuralgia Classification), as presumed
during the DVCS treatment and diagnosed a posteriori when the secondary aesthesiography has been undertaken
(n¼43 patients).
Cutaneous department
SMA Number
of axonal lesions
Example of axonal lesions
diagnosed a posteriori
Trigeminal 2 Maxillary nerve
Occipital 1 Greater occipital nerve
Cervical 4 Posterior branch of the
7th cervical nerve
Brachial 18 Posterior brachial cutaneous nerve
Thoraco-intercostal 10 Lateral cutaneous branch of the
5th intercostal nerve
Lumbo-abdominal 2 Ilioinguinal nerve
Femoral 11 Infrapatellar branch of saphenous nerve
Femoro-cutaneous 1 Lateral femoral cutaneous nerve
Sciatic 12 Lateral calcaneal branches of sural nerve
Sacral 2 Posterior femoral cutaneous nerve
Total 63
Table VI. The 100% of SMA territories (n¼63), in 43 patients investigated and treated with DVCS, disappeared and then the presence of
an underlying hypoaesthesia was revealed in each case.
Aesthesiography
contra-productivea a priori Allodynography
Secondary aesthesiography
a posteriori
63 63 63
Absence of observable
tissue damage
SMA Underlying
hypoaesthesia
aIt is possible to apply a force of 15 g in the centre of a SMA territory, the patient being able to bear it at the precise time of application,
although it may exceed the pain threshold defined by the patient on the VAS scale. However, such stimulation in the centre of the SMA
territory at that step is highly contra-productive as it will in most cases increase later on the spontaneous pain, as well as the stimulus-evoked
pain, during hours, if not days. In other words, such inadequate intervention at that step has the devastating consequence to exacerbate
the SMA.
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approach can be generalized to the entire body
surface (Tables III and V). The aim of the present
paper was to report on the switch from a SMA
territory into a hypoaesthetic territory as a result of
the somatosensory rehabilitation. The specific clin-
ical aspects of these basic properties will be described
and discussed in more detail elsewhere. The key
finding of the present work is the progressive
shrinkage of the SMA territory until complete
disappearance. These regions demonstrating static
mechanical allodynia are also the same regions where
an underlying hypoaesthetic territory can be
observed once the allodynia has disappeared. This
observation provides evidence that the SMA was
indeed provoked by a histological loss of large A
afferent fibres. This information clearly indicates that
nerve damage is often the source of neuropathic pain,
and that the allodynia is most often referred to the
zone of greatest denervation: one can conclude that
static mechanical allodynia is indeed a paradoxical
painful hypoaesthesia. We presume that the under-
lying mechanical hypoaesthetic territory, revealed
here after removal of the SMA territory, was already
present from the beginning (immediately after the
peripheral nerve lesion), but was already masked at
that time by the painful SMA territory. The proposed
therapy was thus a two-stage approach: first, remove
the SMA territory by gentle tactile stimulation
applied at the periphery of the painful zone and
then to recover from the hypoaesthesia. The gentle
vibrotactile counter-stimulation is applied at the
periphery of the SMA territory, which is perceived
as comfortable for the patient (Figure 5). The
territory on which the DVCS is applied has to
Figure 6. Distribution of the 63 SMA territories as a function of their corresponding rainbow pain scale at the date of the
first somatosensory testing (bottom rectangle of each column; the sum of the numbers in the bottom area of all column is
63). Time goes from bottom to top. For further analysis, the 22 colour transitions in the rainbow pain scale below the thick
horizontal line have been discarded due to insufficient numbers (5 from red to orange, 5 from orange to yellow, and 12 from
yellow to green). The upper part of the figure shows the distribution of the 158 colour transitions in the rainbow pain scale
during the somatosensory rehabilitation. The time course of disappearance of the 158 steps of the rainbow pain scales is
presented in Figure 7.
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belong to the same spinal dermatome, because no
effect is obtained with extra segmental vibrotactile
stimulation. Interestingly, when the treatment was
interrupted after the first phase, namely, removal of
the SMA territory, without proceeding to the
recovery from the hypoaesthesia, then the SMA re-
appears after a few weeks. In other words, the
shrinkage and disappearance of the SMA territory is
in itself not sufficient to eliminate the stimulus-
evoked neuropathic pain over the long term; the
second stage of treating the hypoaesthesia being
necessary in order to permanently eliminate the
stimulus-evoked neuropathic pain and the sponta-
neous neuropathic pain.
As a result of the therapy, the SMA territory
progressively shrank. The time course of progressive
SMA territory shrinkage was assessed using either
allodynography or the rainbow pain scale procedure,
but never using both simultaneously (Noe¨l et al.
2005).2 When both were tested during the same
session, the patient had too much pain for a couple of
hours, or even days. Moreover, when both were
tested during the same session, instead of observing a
progressive SMA territory shrinkage, the rainbow
pain scale increased at the next session. For the same
reasons the underlying hypoaesthesia is assessed
using the secondary aesthesiography and then the
PPT procedure, but never using both simulta-
neously. The PPT is therefore conducted during
the session following the disappearance of the SMA
and not during the session in order to avoid a
reappearance of SMA. Additionally, the PPT proce-
dure was adapted to test an underlying hypoaesthesia
into a short-form PPT: the application of the three
aesthesiometers is detected in three series (ADA)
instead of six series (ADADAD).
A robust recovery from SMA thus requires the two
stages of treatment. However, the time point at
which the treatment is initiated does not play a major
role. Indeed, in the present sample of 43 patients,
some suffered from neuropathic pain over a period of
several years (up to 45 years). This observation
indicates that, even if the central sensitization has
been established for a long time, it can still be
reversed, at least enough to eliminate the evoked and
spontaneous pains. The mechanisms underlying the
reversal of central sensitization, in particular how
vibrotactile stimuli may relieve pain, are largely
unknown (Inui et al. 2006). The ‘‘gate control’’
theory has provided a possible mechanism contribut-
ing to this phenomenon (Melzack and Wall 1965),
with the hypothesis that influences of large myeli-
nated inputs inhibit the central transmission of
signals conveyed by nociceptors, occurring in the
dorsal horn of the spinal cord. Based on the precise
timing of activities generated in these two separate
systems of afferent fibres, a recent work suggested
that such inhibition is more likely to occur at cortical
than spinal level (Inui et al. 2006). In line with this
observation, another study using psychophysical and
physiological measures in humans concluded that the
inhibition by large diameter fibres takes place at
supraspinal level (Nahra and Plaghki 2003). The
evoked chronic pain in SMA is elicited by application
of a non-noxious tactile stimulus within the SMA
territory. To be accepted by the patient, the present
therapeutic strategy consists of gentle vibrotactile
stimulation of immediately adjacent zones, on which
the stimulus is perceived as comfortable. The
stimulus applied on the SMA territory activates
centrally (in the spinal cord) a network previously
subjected to the sensitization (leading to the painful
sensation), whereas the tactile stimulus applied on a
comfortable neighbouring skin area elicits activity in
a second network of neurons. One may then
speculate that the second network activated may
exert a progressively increasing down regulation of
the first network underlying the SMA. As a
consequence, the previously sensitized synapses of
the first network may undergo plastic changes
towards a decrease of efficacy, in analogy with the
well-known mechanism of ‘‘long-term depression’’
(LTD), reported for the cerebellum for instance. As
the processes of initiation and maintenance of
allodynia have been compared to LTP (Ji et al.
2003), it is tempting to hypothesize that the
therapeutic removal of the SMA territory is, at least
in part, based on mechanisms close to LTD. The
rehabilitation of hyposensitivity is most likely based
on the neuroplasticity of the somatosensory system
(Woolf and Salter 2006). This hypothesis needs to be
tested experimentally in animal models of allodynia.
Figure 7. Time course of disappearance of painful
hypoaesthesia as a function of the rainbow pain scale.
Going from left to right, time values are mean intervals in
days to switch from one colour of the rainbow pain scale to
the next: switch from 1.5 to 3.6 g (n¼ 19); from 3.6 to 8.7 g
(n¼ 35); from 8.7 to 15 g (n¼ 41); from 15 g (allodyno-
graphy) to underlying hypoaesthesia (secondary aesthesio-
graphy) (n¼ 63).
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As outlined in the Introduction, mechanical
allodynia emphasizes its central sensitization, in
particular in the dorsal root ganglion or in the
dorsal horn (e.g., Woolf 1983; Hendry et al. 1999;
Mannion et al. 1999; Sindrup et al. 1999; Ji and
Woolf 2001; Ji et al. 2003; Sukhotinsky et al. 2004;
Devor 2006). The statement ‘‘The static mechanical
allodynia is a paradoxical painful hypoaesthesia’’
does not contest the most likely central component of
post-injury pain hypersensitivity (Woolf 1983). Few
authors remind us that the aetiology of SMA is a
damaged nerve (e.g., Woolf and Mannion 1999;
Woolf and Salter 2000; Sukhotinsky et al. 2004).
Bennett (1994) presumed that ‘‘Although [. . .] the
absence of suitable testing, it is possible that
neuropathic allodynia is exclusively a disorder of
cutaneous sensibility.’’ Devor (1994) described the
hypersensitivity as restricted mechano-sensitive
tender spots. Rowbotham and Fields (1996)
described the apparent paradox that the sensory
damaged pathways, which are usually associated with
loss of function, are occasionally accompanied by
dramatic evidence of hyperfunction. Scadding and
Koltzenburg (2006) reported that ‘‘touch-evoked
pain in neuropathic conditions is signaled on the
skin by sensitive mechanoreceptors with large mye-
linated axons that normally encode non-painful
tactile events’’. But no one pointed out that the
first consequence of an axotomy is a hypoaesthetic
territory on the skin—it is perhaps too evident—and
that the painful complication of ‘‘tenderness to
touch’’ is located on the same territory as the
hypoaesthesia, which is on the partial cutaneous
territory of partial denervated nerves, even if the
neural mechanisms underlying SMA are presumably
central. Therefore, we conclude that a SMA mapped
using allodynography is, in humans with neuropathic
pain, the sign of a peripheral axotomy of large
myelinated A fibres, which normally evoke non-
painful tactile sensations. This interpretation does
not exclude, in addition, a possible contribution of
the small, unmyelinated fibres.
The surface on the skin of the SMA territory is
usually larger than the hypoaesthetic territory—
extraterritorial pain—as determined by the secondary
aesthesiography but, if the mechanisms of activation,
modulation, or even modification producing pain
hypersensitivity (Woolf and Salter 2000) are not
followed through, we have a situation where the
SMA territory is smaller than the hypoaesthetic
territory.
The time course of disappearance from one
rainbow pain scale value into the next one is not
linear (Figure 7). It takes longer to overcome a green
rainbow pain scale (1.5 g provoking pain) than to
overcome a blue rainbow pain scale (3.6 g). It takes
49.9 daysSD¼ 32.9 days to overcome a green
rainbow pain scale whereas it takes 33.7
daysSD¼ 20.8 days to overcome a blue rainbow
pain scale. These time intervals are values of great
interest for the therapist and the patient, as they allow
estimating the duration of DVCS treatment, that is,
the step by step disappearance of the SMA territory.
Conclusions
The aim of this study was to investigate whether a
SMA territory is modified in the course of the DVCS
treatment. The absence so far in the literature of a
relationship between hypoaesthesia and mechanical
allodynia has been brought about by the fact that they
are distinct expressions of nerve axotomy occurring
at different moments. This study shows the disap-
pearance of a SMA territory, replaced by an under-
lying hypoaesthesia. ‘‘The precise and high quality
mapping of allodynia performed in somatosensory
rehabilitation is a precious source of information for
our understanding of abnormal sensory processing in
neuropathic pain patients’’ (Decosterd 2006).
Therefore, the mapping of SMA territories using
allodynography diagnoses axonal lesions and their
underlying hypoaesthesia. These are painful
hypoaesthesia which are so difficult to cope with.
This conclusion has clinical applications: according
to the Complex Regional Pain Syndrome (CRPS)
Diagnosis Criteria (Bruehl et al. 1999), mechanical
allodynia is considered to be a sensory sign with a
corresponding symptom of ‘‘hyperaesthesia’’ because
the patient himself perceives the stimulus which does
not normally provoke pain as painful. In fact, the
patients, when asked about their sensation, prefer
using the word ‘‘hypersensitivity’’ (Woolf 1983,
1994), ‘‘tenderness’’ (Perttunen et al. 1999), or
‘‘tender’’ in the McGill Pain Questionnaire (Melzack
1975) to describe this phenomenon.
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Notes
1. In this article in French, the PPT was for the first time adapted
to test an underlying hypoaesthesia: the short-form PPT score is
given by the mean value of the force application of the three
aesthesiometers detected in an ADA series. In the original
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method to test an hypoaesthesia, the PPT score was given by the
mean value of the force application of the six aesthesiometers
detected in an ADADAD series.
2. In this chapter in French was first described this procedure to
test during a session either the allodynography or the rainbow
pain scale, but never both simultaneously.
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Appendix A: Experimental protocol for
allodynography
. The stimulus is applied at multiple locations on
the skin.
. The stimulus is arbitrarily fixed at an applied
force of 15 g (pressure: 69.1 g/mm2).
. The pain invariant is defined as 3/10 cm on a
visual analogue scale (VAS) or the pain at
restþ 1 cm (see Figure 3B).
Objective: To map the SMA territory
Material.
. A4, possibly A3 millimetric graph paper.
. 15 g aesthesiometer (Semmes–Weinstein: mark
5.18).
. Visual analogue scale of pain understood by the
patient.
Test procedure. The limb to be examined should be
stable, if necessary stabilized by the examiner’s hand.
Type of stimulation. The pressure to be applied to
the aesthesiometer by the therapist is the minimum
force required to bend the nylon filament. At the
beginning, skin stimulation is rapid and then, as the
precise zone is approached, stimulation should be for
2 s and the interval between questions 8 s. The
interstimulus interval (ISI) is thus 10 s, to be counted
mentally.
Choice of the pain invariant. Great attention is
required during the initial testing. In particular, the
patient is asked, ‘‘Can you imagine a worst
possible pain?’’ A pain for the search of the
allodynic territory is fixed at 3/10 cm. In this way,
a large vertical red line is traced at a pain of 3/10,
which is marked ‘‘STOP’’, thus representing the
pain invariant.
Explanations on the allodynography procedure
are given to the patient: the aesthesiometer is
pressed against the skin of a non-painful limb, and
the patient is told that the place evoking moderate
pain is being sought; the ‘‘STOP’’ mark is shown
to him at the same time. He is asked to look at the
scale and using his finger, to progress along the
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‘‘no pain’’ line to the ‘‘STOP’’ mark when pain
begins to appear. The patient replies by ‘‘STOP’’
when the stimulus provokes a pain corresponding
to 3/10.
Localization. On the longitudinal axis of the limb,
from proximal to distal, the first allodynic point is
found by moving the stimulus site centimetre by
centimetre. The patient is asked if the pain is red
(line colour at 3 cm on the visual analogue scale): if
no, the test is continued moving the stimulus further;
if yes, move the stimulus back from distal to proximal
in order to find a less painful stimulation site. Then,
move again from proximal to distal, but now
advancing millimetre by millimetre in order to find
the first allodynic point along this axis. Mark the final
stimulated site on the paper, trace the axis that was
followed, and add an arrow (see Figure 1). Carry out
the procedure on the perpendicular axes. Finally,
trace a polygon by joining the border sites obtained
along the various axes investigated.
Result. This is the 15 g allodynic (SMA) territory for a
pain invariant of 3/10 cm on a VAS.
Appendix B: Experimental protocol for the
rainbow pain scale
. The tactile stimulus is delivered using the
following seven aesthesiometers: 0.03 g (red);
0.2 g (orange); 0.7 g (yellow); 1.5 g (green);
3.6 g (blue); 8.7 g (indigo); 15 g (violet). They
correspond to every other monofilament in the
Semmes–Weinstein kit of 20.
. The visual analogue pain scale validated by the
patient during allodynography is also used: the
pain invariant is defined as 3/10 cm on a visual
analogue scale (VAS) or the pain at restþ 1 cm.
Objective: To determine the severity of the SMA by
determining the slightest aesthesiometer, from red to violet,
provoking pain
Material
. A4, possibly A3 millimetric graph paper.
. Seven aesthesiometers: 0.03 g (Semmes–
Weinstein: mark 2.44); 0.2 g (mark: 3.22);
0.7 g (mark: 3.84); 1.5 g (mark: 4.17); 3.6 g
(mark: 4.56); 8.7 g (mark: 4.93); 15 g (mark:
5.18).
. The VAS validated by the patient during
allodynography.
Test procedure. The limb to be examined should be
stable, if necessary stabilized by the examiner’s hand.
Type of stimulation. The pressure to be applied to the
aesthesiometer by the therapist is the minimum force
required to bend the nylon filament. The application
of the stimulus must last 2 s with an interval of 8 s
between questions. The interstimulus interval is thus
10 s, to be counted mentally.
Choice of the pain invariant. Same as above for
allodynography.
Explanations on the rainbow pain scale procedure
are given to the patient: the aesthesiometer is pressed
against the non-painful limb, making it clear that it is
not the same one as used for allodynograhy. The
patient is told that a search is being made for the
place where moderate pain is provoked while, at the
same time, he is shown the ‘‘STOP’’ mark on the
VAS. Using the index finger, the patient is instructed
to advance along the ‘‘no pain’’ line to the ‘‘STOP’’
mark when pain begins to appear. The patient says
‘‘Stop’’, when the stimulus provokes a pain of 3/10
on the VAS.
Localization. Within the allodynic territory, using
the 0.03 g aesthesiometer along the long axis of the
limb, from proximal to distal, the first painful point
is determined, advancing centimetre by centimetre.
The patient is asked if the pain is red. If not, the
test is continued. If yes, the aesthesiometer is
moved back from distal to proximal in order to
find a less painful point. Then, it is moved forward
along the same axis from proximal to distal, but
now advancing millimetre by millimetre, in order
to find the first red point on the rainbow pain
scale. The site found on the paper is marked in
RED, the axis that was followed traced, and an
arrow added. The same procedure is performed on
the perpendicular axes. Finally, a polygon is traced
by joining up the registered sites. In such a case,
the patient presents a red rainbow pain scale of
0.03 g, corresponding to a pain invariant of 3/10 cm
on the VAS.
In case the 0.03 g aesthesiometer does not provoke
pain, which was fortunately the case in most patients,
the whole procedure is repeated with the ‘‘orange’’
aesthesiometer (0.2 g). If the latter does not provoke
pain either, the procedure is repeated with the
‘‘yellow’’ aesthesiometer (0.7 g), and so on until the
first painful aesthesiometer is found. In the most
favourable case for the patient, it will be the one used
for the allodynography, namely, the violet aesthesi-
ometer (15 g). Whenever the aesthesiometer provok-
ing pain is found, the determination of the border
points is done along the different axes to obtain the
final polygon (as explained above).
Result. The patient consequently presents a rainbow
pain scale of a colour corresponding to the first
painful aesthesiometer, going from red to violet,
using a pain invariant of 3/10 cm on the VAS.
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Appendix C: Experimental protocol for the sec-
ondary aesthesiography
Objective: To map the boundaries of the underlying
hypoaesthetic territory present after disappearance of the
SMA territory
Material
. A4 millimetric graph paper for the hand or
possibly A3 for the hand together with the
forearm.
. Set of 20 Semmes–Weinstein pressure
aesthesiometers.
Test procedure. The limb to be examined should be
stable, if necessary stabilized by the examiner’s hand.
Type of stimulation. The pressure to be applied to the
aesthesiometer by the therapist is the minimum force
required to bend the nylon filament. The stimulation
on the skin should only last for 2 s and the
interstimulus interval should be 8 s. The time
between each monofilament application is thus
10 s, to be counted mentally.
Choice of aesthesiometer by the therapist. In a descend-
ing series, the last aesthesiometer detected on the
contralateral side is determined, for instance, it is
0.1 g (mark: 2.83) on the palm and 0.2 g (mark: 3.22)
on the dorsal face of the hand. Subsequently, select
two aesthesiometers next to the first aesthesiometer
detected, both in the ascending and descending
directions. This series of five aesthesiometers is then
used for delineating the hypoaesthetic territory. If the
aesthesiometer is too small, the contour will be
imprecise. If on the contrary, it is too large, there will
be no hypoaesthetic territory.
Explanations on the determination of the second-
ary aesthesiography are given to the patient: the
aesthesiometers are shown to the patient, who is told
that he is going to be touched by some of them in
order to determine the territory where he feels less
than normal. He is asked to look away by turning his
head slightly to the side. The patient replies by
touched as soon as he detects the stimulus.
Localization. In order to help the therapist trace the
final polygon, it is easier to place the graph paper
besides the hand and parallel to it, so that he only has
to mentally effect a transfer between the hand and the
recording paper.
Longitudinal axis. The first point not detected by the
patient is identified. On the longitudinal axis, from
the proximal to the distal, the first stimulating site
not perceived by the patient is determined, advan-
cing centimetre by centimetre. Move back from
distal to proximal in order to find the first detected
point. Finally, the first point not detected along this
axis is found by moving forward again from proximal
to distal, but now advancing millimetre by
millimetre.
Transverse axis. Search the first point not detected by
the patient along the axis perpendicular to the
presumed damaged nerve. On the axis from right
to left (e.g., for a palm face of a right hand, in case of
lesion of the ulnar nerve), search the first point not
detected by the patient, advancing centimetre by
centimetre. Then return towards the right to find the
first point detected. The next step is to return
towards the left, but advancing millimetre by
millimetre, in order to find the first point not
detected on the transverse axis. Finally, mark the
point found on the paper and trace with an arrow the
axis that was considered. If necessary, continue the
search for other points on the lines: transverse axis of
the metacarpal heads, transverse axis of the PIP,
longitudinal axis from distal to proximal, etc.
Result. Trace a polygon joining up the points
determined, reflecting the extent and position of
the underlying hypoaesthetic territory.
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